التفاصيل البيبلوغرافية
| العنوان: |
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. |
| المؤلفون: |
Caravaca-Fontán, Fernando, Stevens, Kate, Padrón, Maite, Huerta, Ana, Montomoli, Marco, Villa, Juan, González, Fayna, Vega, Cristina, Mendoza, Manuel López, Fernández, Loreto, Shabaka, Amir, Rodríguez-Moreno, Antolina, Martín-Gómez, Adoración, Labrador, Pedro J, Andújar, Alicia Molina, Soler, M Carmen Prados, Martín-Penagos, Luis, Yerovi, Estefanía, Zahonero, Laura Medina, Flor, José Carlos De La |
| المصدر: |
Nephrology Dialysis Transplantation; Feb2024, Vol. 39 Issue 2, p328-340, 13p |
| مصطلحات موضوعية: |
GLUCOSE transporters, SODIUM-glucose cotransporters, SODIUM-glucose cotransporter 2 inhibitors, NEPHRITIS, GLOMERULAR filtration rate, GLOMERULONEPHRITIS, BODY mass index, KIDNEY glomerulus diseases |
| مستخلص: |
Background The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. Methods This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. Results Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin–angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8% and –10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30–0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: –3.7 versus –5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. Conclusions The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nephrology Dialysis Transplantation is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
